Drug Profile
Human adult bone-marrow derived somatic cell therapy - Neuronyx
Alternative Names: hABM-SC therapy - Neuronyx; Human adult stem cell therapy - Neuronyx; NX CP105Latest Information Update: 16 Aug 2011
Price :
$50
*
At a glance
- Originator Neuronyx
- Class Cardiovascular therapies; Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial infarction; Retinal disorders; Stroke; Wounds
Most Recent Events
- 16 Aug 2011 Discontinued - Phase-I for Myocardial infarction in USA (Intracoronary)
- 16 Aug 2011 Discontinued - Preclinical for Retinal disorders in USA (Ophthalmic)
- 16 Aug 2011 Discontinued - Preclinical for Stroke in USA (Parenteral)